Skip to main content Back to Top
Advertisement

10/23/2024

Ropivacaine Injection

Products Affected - Description

    • Naropin injection, Fresenius Kabi, 7.5 mg/mL, 20 mL Steripak plastic ampule, 5 count, NDC 63323-0287-20
    • Ropivacaine injection, Eugia US, 2 mg/mL, 100 mL infusion bottle, 25 count, NDC 55150-0196-99
    • Ropivacaine injection, Eugia US, 5 mg/mL, 20 mL vial, 25 count, NDC 55150-0197-20
    • Ropivacaine injection, Eugia US, 5 mg/mL, 30 mL vial, 25 count, NDC 55150-0198-30
    • Ropivacaine injection, Hikma, 2 mg/mL, 20 mL vial, 10 count, NDC 00143-9263-10

Reason for the Shortage

    • Akorn ceased operations in February 2023.
    • Amneal has ropivacaine available.
    • Baxter has ropivacaine available.
    • Eugia has ropivacaine on shortage due to increased demand.
    • Fresenius Kabi has ropivacaine available. Multiple presentations were discontinued in mid-2024.
    • Hikma did not provide a reason for the shortage.
    • Pfizer discontinued ropivacaine in August 2022.
    • Somerset Therapeutics has ropivacaine available.
    • Sagent has ropivacaine available.
    • Viatris has ropivacaine available.

Available Products

    • Naropin injection, Amneal, 2 mg/mL, 100 mL premixed bag, 24 count, NDC 70121-1732-09
    • Naropin injection, Amneal, 2 mg/mL, 200 mL premixed bag, 24 count, NDC 70121-1733-09
    • Naropin injection, Fresenius Kabi, 10 mg/mL, 10 mL vial, 25 count, NDC 63323-0288-11
    • Naropin injection, Fresenius Kabi, 10 mg/mL, 20 mL vial, 25 count, NDC 63323-0288-21
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 10 mL vial, 25 count, NDC 63323-0285-13
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 100 mL infusion bottle, 1 count, NDC 63323-0285-65
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 20 mL vial, 25 count, NDC 63323-0285-23
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 200 mL infusion bottle, 1 count, NDC 63323-0285-64
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 100 mL infusion bottle, 1 count, NDC 63323-0286-00
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 20 mL vial, 25 count, NDC 63323-0286-23
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 200 mL infusion bottle, 1 count, NDC 63323-0286-63
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 30 mL vial, 25 count, NDC 63323-0286-35
    • Naropin injection, Fresenius Kabi, 7.5 mg/mL, 20 mL vial, 25 count, NDC 63323-0287-21
    • Ropivacaine injection, Baxter, 10 mg/mL, 20 mL vial, 10 count, NDC 43066-0027-10
    • Ropivacaine injection, Baxter, 2 mg/mL, 20 mL vial, 10 count, NDC 43066-0015-10
    • Ropivacaine injection, Baxter, 5 mg/mL, 20 mL vial, 10 count, NDC 43066-0019-10
    • Ropivacaine injection, Baxter, 5 mg/mL, 30 mL vial, 10 count, NDC 43066-0023-10
    • Ropivacaine injection, Eugia US, 10 mg/mL, 10 mL vial, 25 count, NDC 55150-0200-10
    • Ropivacaine injection, Eugia US, 10 mg/mL, 20 mL vial, 25 count, NDC 55150-0201-20
    • Ropivacaine injection, Eugia US, 2 mg/mL, 20 mL vial, 25 count, NDC 55150-0195-20
    • Ropivacaine injection, Eugia US, 7.5 mg/mL, 20 mL vial, 25 count, NDC 55150-0199-20
    • Ropivacaine injection, Mylan (Viatris), 2 mg/mL, 100 mL premixed bag, 10 count, NDC 67457-0798-99
    • Ropivacaine injection, Mylan (Viatris), 2 mg/mL, 200 mL premixed bag, 10 count, NDC 67457-0799-99
    • Ropivacaine injection, Sagent, 2 mg/mL, 100 mL premixed bag, 10 count, NDC 25021-0671-82
    • Ropivacaine injection, Sagent, 2 mg/mL, 200 mL premixed bag, 10 count, NDC 25021-0671-87
    • Ropivacaine injection, Sagent, 5 mg/mL, 100 mL premixed bag, 10 count, NDC 25021-0652-82
    • Ropivacaine injection, Sagent, 5 mg/mL, 200 mL premixed bag, 10 count, NDC 25021-0652-87
    • Ropivacaine injection, Somerset Therapeutics LLC, 10 mg/mL, 20 mL vial, 10 count, NDC 70069-0067-10
    • Ropivacaine injection, Somerset Therapeutics LLC, 10 mg/mL, 20 mL vial, 25 count, NDC 70069-0067-25
    • Ropivacaine injection, Somerset Therapeutics LLC, 2 mg/mL, 10 mL vial, 10 count, NDC 70069-0061-10
    • Ropivacaine injection, Somerset Therapeutics LLC, 2 mg/mL, 10 mL vial, 25 count, NDC 70069-0061-25
    • Ropivacaine injection, Somerset Therapeutics LLC, 2 mg/mL, 20 mL vial, 10 count, NDC 70069-0062-10
    • Ropivacaine injection, Somerset Therapeutics LLC, 2 mg/mL, 20 mL vial, 25 count, NDC 70069-0062-25
    • Ropivacaine injection, Somerset Therapeutics LLC, 5 mg/mL, 20 mL vial, 25 count, NDC 70069-0063-25
    • Ropivacaine injection, Somerset Therapeutics LLC, 5 mg/mL, 30 mL vial, 1 count, NDC 70069-0064-01
    • Ropivacaine injection, Somerset Therapeutics LLC, 5 mg/mL, 30 mL vial, 10 count, NDC 70069-0064-10
    • Ropivacaine injection, Somerset Therapeutics LLC, 5 mg/mL, 30 mL vial, 25 count, NDC 70069-0064-25

Estimated Resupply Dates

    • Eugia has ropivacaine 2 mg/mL 100 mL bottles and 5 mg/mL 20 mL and 30 mL vials on back order and the company cannot estimate a release date.
    • Fresenius Kabi has short-dated ropivacaine 7.5 mg/mL 20 mL vials in Steripaks with an expiration date of < 7 months.
    • Hikma has ropivacaine 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date.

Updated

Updated October 23, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 27, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT